Evidence map›Paper›PMID 42020880›Full record

ArticleInflammation2026

Dock2 Protects Colitis by Facilitating Akkermansia Colonization via Suppressing IL-22-Reg3 Activity.

Min Lu, Shaoting Xu, Ying Tan, Jianping Deng, Bingbing Feng, Ding Qiu, Xinying Wang, Haiyang Sun, Kaile Ji, Bowen Zhu and 8 more

Abstract read
In one paragraph

Article in Inflammation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Min LuDepartment of Gastroenterology, Guangdong Province, Zhujiang Hospital, Southern Medical University, 253 Gongye Dadao Zhong, Guangzhou, 510280, China.
Shaoting XuInstitute of Precision Medicine, Guangdong Province, The First Affiliated Hospital, Sun Yat-Sen University, No.58, Zhong Shan Er Lu, Guangzhou, 510080, China.
Ying TanInstitute of Precision Medicine, Guangdong Province, The First Affiliated Hospital, Sun Yat-Sen University, No.58, Zhong Shan Er Lu, Guangzhou, 510080, China.
Jianping DengInstitute of Precision Medicine, Guangdong Province, The First Affiliated Hospital, Sun Yat-Sen University, No.58, Zhong Shan Er Lu, Guangzhou, 510080, China.
Bingbing FengInstitute of Precision Medicine, Guangdong Province, The First Affiliated Hospital, Sun Yat-Sen University, No.58, Zhong Shan Er Lu, Guangzhou, 510080, China.
Ding QiuInstitute of Precision Medicine, Guangdong Province, The First Affiliated Hospital, Sun Yat-Sen University, No.58, Zhong Shan Er Lu, Guangzhou, 510080, China.
Xinying WangInstitute of Precision Medicine, Guangdong Province, The First Affiliated Hospital, Sun Yat-Sen University, No.58, Zhong Shan Er Lu, Guangzhou, 510080, China.
Haiyang SunInstitute of Precision Medicine, Guangdong Province, The First Affiliated Hospital, Sun Yat-Sen University, No.58, Zhong Shan Er Lu, Guangzhou, 510080, China.
Kaile JiInstitute of Precision Medicine, Guangdong Province, The First Affiliated Hospital, Sun Yat-Sen University, No.58, Zhong Shan Er Lu, Guangzhou, 510080, China.
Bowen ZhuInstitute of Precision Medicine, Guangdong Province, The First Affiliated Hospital, Sun Yat-Sen University, No.58, Zhong Shan Er Lu, Guangzhou, 510080, China.
Shixian HuInstitute of Precision Medicine, Guangdong Province, The First Affiliated Hospital, Sun Yat-Sen University, No.58, Zhong Shan Er Lu, Guangzhou, 510080, China.
Xueting WuDepartment of Gastroenterology and Hepatology, Guangdong Province, The First Affiliated Hospital, Sun Yat-Sen University, No.58, Zhong Shan Er Lu, Guangzhou, 510080, China.
Minhu ChenDepartment of Gastroenterology and Hepatology, Guangdong Province, The First Affiliated Hospital, Sun Yat-Sen University, No.58, Zhong Shan Er Lu, Guangzhou, 510080, China.
Yoichiro IwakuraCenter for Animal Disease Models, Research Institute for Biomedical Sciences, Tokyo University of Science, Noda, Chiba, 278-0022, Japan.
Xinying WangDepartment of Gastroenterology, Guangdong Province, Zhujiang Hospital, Southern Medical University, 253 Gongye Dadao Zhong, Guangzhou, 510280, China. sunwingwxy@163.com.
Rui FengDepartment of Gastroenterology and Hepatology, Guangdong Province, The First Affiliated Hospital, Sun Yat-Sen University, No.58, Zhong Shan Er Lu, Guangzhou, 510080, China. fengr7@mail.sysu.edu.cn.
Yangfan QiDushu Lake Higher Education Town, Cancer Institute, Soochow University, Jiangsu Province, 199 Renai Road, Suzhou Industrial ParkSuzhou, 215123, China. yfqi@suda.edu.cn.
Ce TangInstitute of Precision Medicine, Guangdong Province, The First Affiliated Hospital, Sun Yat-Sen University, No.58, Zhong Shan Er Lu, Guangzhou, 510080, China. tangc7@mail.sysu.edu.cn.

Funding

Basic and Applied Basic Research Foundation of Guangdong Province 2021A1515110208National Natural Science Foundation of China 82070564
6 · The paper itself

Abstract

Dedicator of cytokinesis 2 (DOCK2) is a guanine nucleotide exchange factor upregulated in patients with inflammatory bowel disease (IBD), yet its role in intestinal homeostasis remains obscure. Here, we show that both systemic and T cell–specific Dock2-deficient mice develop exacerbated chemical-induced colitis, characterized by reduced CD8⁺ T cells and impaired IFN-γ production, alongside elevated IL-22 and Reg3γ/β antimicrobial peptides (AMPs), and accompanied with decreased colonization of Akkermansia (A.) muciniphila, a beneficial Verrucomicrobia species. Reg3γ/β expression was diminished in IL-22– and RORγt–deficient mice, and both AMPs inhibited A. muciniphila growth. Co-housing with wild-type mice or A. muciniphila reconstitution rescued colitis severity in Dock2-deficient mice. Pharmacologic inhibition of Dock2-Rac1 signaling suppressed IFN-γ in murine and human T cells. Mechanistically, IFN-γ restricted IL-22 by enhancing H3K27 trimethylation on Ahr promoter and suppressing AHR transcription. These findings identify a Dock2–IFN-γ–IL-22–Reg3 axis that controls commensal microbiota and colitis. Targeting Dock2 signaling may offer new therapeutic opportunities in IBD.

Indexed as

ColitisGTPase-Activating ProteinsGuanine Nucleotide Exchange FactorsInterleukinsPancreatitis-Associated ProteinsAnimalsHumansInterferon-gammaInterleukin-22MiceMice, Inbred C57BLMice, KnockoutDOCK2 protein, mouseGTPase-Activating ProteinsGuanine Nucleotide Exchange FactorsInterferon-gammaInterleukin-22InterleukinsPancreatitis-Associated ProteinsReg3b protein, mouseReg3g protein, mouseAkkermansiaDock2Gut microbiotaIBDIFN-γIL-22Reg3

Identifiers

PMID42020880
PMCPMC13236751

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.